AliveCor Kardia 12L Receives CE Mark for European Launch

AliveCor announced on April 15, 2026, that it has received the CE Mark (Conformité Européenne) for its Kardia 12L electrocardiogram (ECG) system. This regulatory approval allows the U.S.-based medtech company to launch its portable, AI-powered cardiac diagnostic tool in the European market.

The Kardia 12L is described as the world’s first handheld 12-lead ECG system that integrates artificial intelligence. The device is specifically designed for health care professionals (HCPs) to provide a portable alternative to traditional, bulky 10-lead ECG carts often used in clinical environments.

The initial European rollout will focus on five primary markets: France, Germany, Italy, Spain, and the United Kingdom.

Technical Design and AI Integration

The Kardia 12L system utilizes a unique single-cable design and five electrodes to capture cardiac data. This hardware configuration is intended to simplify the ECG process for clinicians, reducing the physical footprint of the equipment while maintaining diagnostic depth.

The system is powered by KAI 12L AI technology. This AI integration enables the device to detect 35 different cardiac determinations. Among these capabilities is the detection of acute myocardial infarction (MI) and the most common types of cardiac ischemia.

By combining a portable form factor with AI-driven analysis, the system aims to expedite access to critical heart data, potentially reducing the time required to identify life-threatening cardiac events in settings where traditional equipment is impractical.

Clinical Impact and Market Strategy

The expansion into Europe follows the device’s application in the United States, where it has been used to detect more than 4,000 heart attacks.

AliveCor’s strategy focuses on increasing the accessibility of high-quality cardiac care within the European Union. The company intends to deploy the technology in clinical settings where the mobility of a handheld device offers a significant advantage over stationary diagnostic carts.

Securing CE Mark for the Kardia 12L is a defining moment in our strategy to scale AliveCor’s global footprint. Our priority is to get this life-saving technology into the hands of as many clinicians as possible, especially in settings where traditional, bulky ECG carts simply aren’t practical. By simplifying the hardware without sacrificing diagnostic depth, we are fundamentally improving access to high-quality cardiac care and reducing the burden of cardiovascular disease in the EU.

Simona Esposito, Senior Vice President of Sales, Global Markets at AliveCor

The receipt of the CE Mark allows AliveCor to scale its global footprint by introducing AI-powered cardiology tools to a broader range of European clinicians, focusing on the reduction of cardiovascular disease burdens through faster and easier detection of cardiac conditions.